Home › Companies › CLDX

Celldex Therapeutics, Inc.

CLDX Lead: Phase 3 1 Biotech Distilled article ↓

Most recent annual filing: 2026-02-15

Pipeline (7 active programs)

barzolvolimab

CDX-0159

Protein Target: KIT

Chronic Spontaneous Urticaria Phase 3 subcutaneous
Symptomatic Dermographism Phase 3 subcutaneous
Prurigo Nodularis Phase 2 subcutaneous
Atopic Dermatitis Phase 2 subcutaneous
Chronic Inducible Urticaria Phase 3 subcutaneous

CDX-622

Protein Target: TSLP, SCF

Asthma Phase 1 intravenous
Undisclosed indication

Technology platforms

Bispecific Antibody Platform

Next generation bispecific antibody platform supporting pipeline expansion with additional candidates for inflammatory diseases. Targets selected based on new science and compatibility with existing antibody programs in bispecific formats. Focus on emerging pathways controlling inflammatory diseases.

Discontinued (1)

barzolvolimab — Eosinophilic Esophagitis · mast cell depletion did not result in improvement in EoE symptoms or endoscopic assessment compared to placebo

Biotech Distilled coverage (1)

2026-04-16 Celldex Therapeutics (CLDX) - Scientific Deep Dive for Barzolvolimab and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.